DDInter840 DDInter1658
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Granisetron {u} (Compound) resembles {v} (Compound) Hyoscyamine
Granisetron {u} (Compound) resembles {v} (Compound) Atropine
Granisetron {u} (Compound) binds {v} (Gene) CYP3A4
Granisetron {u} (Compound) upregulates {v} (Gene) CASP10
Granisetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Granisetron {u} (Compound) downregulates {v} (Gene) HSPA1A
Granisetron {u} (Compound) causes {v} (Side Effect) Hepatic enzyme increased
Granisetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Granisetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Granisetron (Compound) resembles Hyoscyamine (Compound)
Granisetron (Compound) resembles Atropine (Compound)
Granisetron (Compound) binds CYP3A4 (Gene)
Granisetron (Compound) upregulates CASP10 (Gene)
Granisetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Granisetron (Compound) downregulates HSPA1A (Gene)
Granisetron (Compound) causes Hepatic enzyme increased (Side Effect)
Granisetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Granisetron may cause a minor interaction that can limit clinical effects when taken with Modafinil
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib